An agonist of the IL-2 pathway in combination with nivolumab is being currently assessed in clinical trials for multiple human cancers as it demonstrated promising results in a phase I trial regarding clinical response and activation of tumor-infiltrating CD8 T cells [10]. Here, CD8A is linked to neoplasm.